Tango Therapeutics (TNGX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Laura Prendergast.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Laura Prendergast’s rating is based on the strategic positioning of Tango Therapeutics’ vopimetostat (vopi) as a potential best-in-class PRMT5 inhibitor, particularly in the treatment of second-line pancreatic ductal adenocarcinoma (PDAC). The company’s plan to initiate a Phase 3 trial in 2026, along with the expectation of vopi’s approval by the first quarter of 2029, supports a promising outlook. Prendergast anticipates that vopi could achieve significant market penetration and generate substantial revenue, with the possibility of these estimates being conservative.
Another factor influencing the Buy rating is the potential synergy between vopi and RVMD’s RAS(ON) inhibitors, which could enhance efficacy and durability in first-line PDAC treatment. The upcoming combination data in 2026 is seen as a critical milestone that could further de-risk the investment. Additionally, the company’s cash runway into 2028 and the broader strategic approach in the evolving PDAC landscape contribute to the positive assessment. Prendergast also notes that the overlap in shareholder base between RVMD and Tango Therapeutics suggests a strong setup for Tango to excel in the post-darax setting.
In another report released on November 17, B. Riley Securities also maintained a Buy rating on the stock with a $14.00 price target.